Opdivo, Eliquis pump up Bristol-Myers' Q1, and its 2016 forecast, too


It was good to be Bristol-Myers Squibb in the first quarter.

The New Jersey pharma giant came up with monster sales for Q1, posting a top-line haul of $4.39 billion to surpass analysts’ $4.27 billion expectations. In turn, EPS also beat out forecasts, coming in at 74 cents to best 65-cent consensus estimates by 14%.

That showing put the company’s guidance on the rise, too. Bristol-Myers ($BMY) now expects low double-digit growth in revenue for 2016, an improvement on the mid-single-digit increase it predicted earlier. And EPS should check in between $2.50 and $2.60 for the year, up from its earlier prediction of $2.30 to $2.40.

Webinar This Week

OTC Innovation to Avoid Stagnation: Survey Insights, Expert Advice, and Latest Technologies to Boost Your Product’s Performance

Join us for a complimentary webinar on November 13 at 11am ET / 8am PT. Listen to industry experts as they analyze the critical role of innovation in OTC products, and strategies for achieving it.

So how did BMS get there? It started with high-flying immuno-oncology med Opdivo, which generated $704 million for the quarter to knock aside expectations of $587 million, Evercore ISI analyst Mark Schoenebaum wrote in a note to clients. More than $1 million of that beat came from its performance in the U.S., where it raked in $594 million to squash $489.1 million expectations.

BMS has taken the oncology field by storm since first launching the newcomer in melanoma. The product--up against Merck ($MRK) competitor Keytruda--now also boasts indications in non-small-cell lung cancer and kidney cancer, and it recently posted strong data in head and neck cancer, its next frontier.

But Bristol-Myers got a big boost from drugs outside its oncology portfolio, too. For one, Eliquis--a next-gen anticoagulant it shares with Pfizer ($PFE)--landed $734 million in quarterly sales. That’s a far cry from the paltry $146 million it posted in all of 2013, and it also shattered Wall Street estimates of $622.6 million. Since rebounding from the slow start, Eliquis has been giving rivals Pradaxa from Boehringer Ingelheim and Xarelto from Bayer and Johnson & Johnson ($JNJ) a run for their money, and BMS execs said earlier this year that they expect their med to overtake them both.

Even hep C revenues, for which BMS “has continuously cautioned for a slow-down,” surprised the Street, ringing up at $427 million versus a consensus of $412 million, Bernstein analyst Tim Anderson wrote in a note to investors. “This franchise continues to hold on relatively well” despite hefty competition from companies including Gilead ($GILD) and AbbVie ($ABBV), he said.

But while the drugmaker may be sitting pretty now, it can’t let up in any of those crowded areas if it wants to retain its slice of the pie--especially immuno-oncology, Anderson noted.

BMS “certainly dominates the I/O landscape in the nearer-term, but given the relatively compressed timelines in I/O, with various competitors like Merck, Roche and AstraZeneca not being too far behind, how market shares settle out over the long term remains difficult to forecast accurately,” he wrote.

- read the release 

Special Report: The top 15 pharma companies by 2014 revenue - Bristol-Myers Squibb

Related Articles:
Opdivo gives head and neck cancer patients a shot at 12-month survival
BMS expects fast-growing Eliquis to take the lead over Xarelto, Pradaxa​
Bristol-Myers immunotherapies soar, but Eliquis haul tops the charts

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

The role of distributors like AmerisourceBergen, is to ensure patients can get access to therapies, no matter where they present.